A Phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a potential medical drug that functions by inhibiting a Phosphoinositide 3-kinase enzyme which is part of the PI3K/AKT/mTOR pathway, which plays a key role in cancer. Inhibiting this pathway often suppresses tumor growth. There are a number of different classes and isoforms of PI3Ks. Class 1 PI3Ks have a catalytic subunit known as p110, with four types (isoforms) - p110 alpha, p110 beta, p110 gamma and p110 delta. The inhibitors being studied inhibit one or more isoforms of the class I PI3Ks.

Neve's mother could only wait and watch and hope as her daughter battled childhood leukemia.
Neve's mother could only wait and watch and hope as her daughter battled childhood leukemia.
Neve's mother could only wait and watch and hope as her daughter battled childhood leukemia.

In the next part of his Myeloproliferative disorders video series, hematologist Ruben Mesa, M.D., of Mayo Clinic in Arizona, discusses treatment of Chronic Myeloid Leukemia.
In the next part of his Myeloproliferative disorders video series, hematologist Ruben Mesa, M.D., of Mayo Clinic in Arizona, discusses treatment of Chronic Myeloid Leukemia.